Lesson
Build the Glycylcycline From Scaffold to Translation Arrest
Tigecycline extends the tetracycline scaffold with a glycylamido substitution. It binds the bacterial 30S subunit, blocks aminoacyl-tRNA entry into the ribosomal A site, and prevents peptide elongation.
- Glycylcycline scaffold
- 30S ribosome
- A site
- Aminoacyl-tRNA
- Bacteriostatic activity
The side chain reduces vulnerability to common tetracycline resistance.
Tigecycline occupies the bacterial translation machinery.
The next charged tRNA cannot enter the A site.
Protein synthesis and bacterial growth slow.
The scaffold predicts both advantage and liability
Tigecycline retains the fused tetracycline core but carries a glycylamido substitution. That change helps it evade many common tetracycline efflux and ribosomal-protection mechanisms while preserving tetracycline-class developmental and hypersensitivity concerns.
The target is the ribosomal A site
Binding to the 30S subunit prevents aminoacyl-tRNA from entering the A site. New amino acids cannot be added efficiently to the growing peptide chain, so bacterial protein production stops.
The usual effect is bacteriostatic
The current label describes tigecycline as generally bacteriostatic, although selected organisms show bactericidal activity in vitro. Clinical decisions should not generalize those exceptions.
Resistance remains possible
Multidrug efflux and other organism-specific mechanisms can reduce susceptibility. A structural advantage never replaces current culture and susceptibility data.
Quick check
Lesson
Read Breadth Without Losing the Gaps
Tigecycline can cover selected susceptible gram-positive, gram-negative, anaerobic, and atypical organisms. Its important gaps include Pseudomonas, Proteus, Providencia, and Morganella.
- MRSA
- Selected enterococci
- Anaerobes
- The four practical gaps
- Multidrug efflux
Use current susceptibility within a supported syndrome.
Pair activity with drainage and source control.
Proteus, Providencia, and Morganella need another plan.
Poor response can reflect acquired or selected resistance.
Gram-positive activity can be useful
The label includes susceptible MRSA within defined skin and intra-abdominal indications. In vitro activity beyond a labeled indication must be kept separate from clinical evidence.
The practical gap list is larger than three P organisms
Pseudomonas, Proteus, and Providencia are commonly memorized, but Morganella also lacks dependable coverage. Suspected infection with any of these organisms requires another active plan.
Anaerobic activity supports the right compartments
Activity against selected Bacteroides and other anaerobes can support complicated intra-abdominal treatment, but drainage and source control remain necessary.
Resistance can bypass the usual advantage
MDR efflux pumps can reduce susceptibility in organisms such as the Acinetobacter baumannii complex. Repeat susceptibility and source assessment when response fails.
Quick check
Lesson
Keep the Syndrome Inside the Evidence
Current adult labeling supports complicated skin and skin structure infection, complicated intra-abdominal infection, and community-acquired bacterial pneumonia. It does not support diabetic foot infection or hospital-acquired pneumonia.
- cSSSI
- cIAI
- Community-acquired bacterial pneumonia
- Diabetic foot exclusion
- HAP and VAP exclusion
Confirm depth, organism, and source control.
Culture and drain whenever possible.
Do not extend this evidence to hospital pneumonia.
Choose an evidence-supported alternative.
Three adult indications define the core
Tigecycline is labeled in adults for cSSSI, cIAI, and community-acquired bacterial pneumonia caused by designated susceptible organisms. Each use still requires a site-specific response and source plan.
Complicated skin is not every skin infection
Depth, systemic response, abscess, necrosis, ischemia, foreign material, and osteomyelitis change both evidence and source-control needs.
Diabetic foot infection is explicitly excluded
Do not infer that a complicated skin indication includes diabetic foot infection. Evaluate ischemia, depth, bone, cultures, debridement, and an evidence-supported regimen.
Hospital pneumonia is also excluded
Tigecycline is not indicated for HAP or VAP. A dedicated trial failed to demonstrate efficacy and showed lower cure and higher mortality in VAP.
Quick check
Lesson
Make the Boxed Warning Change the Decision
All-cause mortality was higher with tigecycline than comparator therapy, with an adjusted risk difference of 0.6 percent. The cause was not established, so the label reserves tigecycline for situations in which alternatives are unsuitable.
- All-cause mortality
- Reserve use
- VAP signal
- Bacteremia
- Alternative analysis
Adjusted risk difference was 0.6 percent.
Lower cure and higher mortality define a firm boundary.
Large tissue distribution weakens primary bacteremia use.
State inactivity, toxicity, allergy, or another concrete limit.
The boxed warning is a selection rule
Mortality was 4.0 percent with tigecycline and 3.0 percent with comparators across 13 trials. The adjusted risk difference was 0.6 percent, and worsening infection was a common pathway to death.
VAP carried the strongest signal
In the VAP subgroup, clinical cure was 47.9 percent with tigecycline and 70.1 percent with comparator therapy. Mortality was 19.1 percent versus 12.3 percent.
Bloodstream exposure is a site problem
A distribution volume of roughly 500 to 700 liters reflects movement far beyond plasma. This can support tissue exposure but makes tigecycline a poor routine choice for primary bacteremia or endovascular infection.
Reserve use must be documented
A defensible plan states indication, organism, source, severity, alternative agents, allergy or toxicity constraints, susceptibility, monitoring, and the condition that will end tigecycline exposure.
Quick check
Lesson
Use Loading, Distribution, and Elimination Together
The adult regimen begins with 100 mg IV, then 50 mg every 12 hours. Tigecycline distributes extensively into tissue, has a long terminal half-life, and is eliminated mainly through biliary and fecal routes.
- 100 mg loading dose
- 50 mg every 12 hours
- Tissue distribution
- Biliary elimination
- No renal adjustment
Establish intended exposure promptly.
Infuse each dose over about 30 to 60 minutes.
High tissue movement means lower intravascular concentration.
Renal impairment and dialysis do not change the dose.
The adult regimen uses a load
Give 100 mg intravenously once, then 50 mg every 12 hours over about 30 to 60 minutes. Omitting the load delays achievement of the intended exposure.
Duration follows the syndrome
The label gives 5 to 14 days for cSSSI and cIAI and 7 to 14 days for community-acquired bacterial pneumonia. Severity, source, microbiology, and progress refine the endpoint.
Distribution explains both strength and weakness
The steady-state distribution volume is roughly 500 to 700 liters. Tissue concentrations can exceed serum, while bone and synovial-fluid exposure may be lower than serum after a single dose.
Renal impairment does not set the dose
Biliary and fecal elimination predominate. No renal adjustment is required, and hemodialysis does not remove a meaningful quantity, but clinical monitoring still follows the patient.
Quick check
Lesson
Make the Vial and the Liver Part of One Prescription
Severe hepatic impairment changes maintenance exposure, and the single-dose vial requires exact reconstitution, withdrawal, final dilution, color inspection, compatibility, and infusion timing.
- Child Pugh C
- 10 mg per mL
- Six percent overage
- Final bag
- Yellow to orange solution
Keep the 100 mg load, then use 25 mg every 12 hours.
Gently swirl one 50 mg single-dose vial.
The extra volume accounts for a 6 percent overage.
Inspect yellow to orange solution and infuse over 30 to 60 minutes.
Severe hepatic impairment changes maintenance only
Child Pugh C uses the usual 100 mg loading dose followed by 25 mg every 12 hours. Mild or moderate hepatic impairment does not require a dose change.
The vial contains a deliberate overage
Reconstitute each 50 mg vial with 5.3 mL of normal saline, D5W, or lactated Ringer solution to 10 mg per mL. Gently swirl until dissolved.
Withdraw five milliliters
Because the vial contains a 6 percent overage, 5 mL of reconstituted solution equals 50 mg. Use one vial for 50 mg and two vials for 100 mg, then transfer into a 100 mL IV bag.
Inspection and line handling prevent avoidable harm
Keep final concentration at or below 1 mg per mL. Use only yellow to orange solution, discard green or black discoloration or particulate matter, and flush a shared line before and after the infusion.
Quick check
Lesson
Separate Common Intolerance From Dangerous Disease
Nausea, vomiting, diarrhea, and abdominal pain are common. Acute pancreatitis, hepatic dysfunction, and C. difficile-associated diarrhea require a different urgency and response.
- Nausea
- Vomiting
- Pancreatitis
- Hepatic dysfunction
- C. difficile
Measure severity, hydration, nutrition, and treatment burden.
Evaluate lipase and pancreatitis without delay.
Injury can worsen after the drug is stopped.
Consider C. difficile during and after therapy.
Nausea and vomiting are common enough to shape selection
Across clinical trials, nausea occurred in 26 percent and vomiting in 18 percent of tigecycline recipients. Severe symptoms can impair hydration, nutrition, and treatment completion.
Pancreatitis can be fatal
New epigastric pain, persistent vomiting, pancreatic-enzyme elevation, or compatible imaging requires prompt evaluation. Consider stopping tigecycline when pancreatitis is suspected.
Liver injury can continue after exposure ends
Bilirubin, transaminases, and prothrombin time can rise, and hepatic dysfunction or failure has occurred. Continue evaluation when abnormalities appear even after discontinuation.
Diarrhea has an antibiotic differential
Frequent watery or bloody diarrhea during therapy or after discharge can reflect C. difficile. Assess severity, timing, abdominal findings, exposures, and testing rather than adding an antimotility drug automatically.
Quick check
Lesson
Put Fibrinogen Beside the Medication List
Tigecycline can cause hypofibrinogenemia and alter coagulation. Warfarin effect and calcineurin-inhibitor exposure require measured follow-up rather than prediction alone.
- Fibrinogen
- PT and aPTT
- INR
- Tacrolimus
- Cyclosporine
Repeat regularly throughout the course.
Use PT, INR, or another suitable test.
Concentrations can rise during coadministration.
Reassess the antibiotic and every competing cause.
Fibrinogen monitoring is explicit
Obtain baseline coagulation parameters including fibrinogen and monitor them regularly during therapy. A falling result should prompt bleeding assessment, liver review, drug necessity, and alternative planning.
Warfarin requires measured anticoagulation
Monitor PT, INR, or another suitable test during coadministration. Avoid guessing direction or changing the dose without integrating the measured response and bleeding risk.
Calcineurin-inhibitor concentrations can rise
Tacrolimus and cyclosporine trough concentrations may increase during tigecycline therapy. Monitor concentrations, kidney function, potassium, blood pressure, neurologic symptoms, and toxicity.
CYP review alone is incomplete
Tigecycline is not expected to alter the major tested CYP pathways, but current labeling still identifies clinically important warfarin and calcineurin-inhibitor monitoring needs.
Quick check
Lesson
Use Developmental Timing, Not Retired Letters
Tigecycline may harm developing teeth and bone. Routine use below age 18 is not recommended, and pregnancy and lactation decisions require current narrative risk assessment.
- Pregnancy
- Lactation
- Tooth development
- Bone growth
- Pediatrics
Developing teeth and bone can be affected.
Use only when no suitable alternative is available.
Duration and infant-exposure reduction belong in the decision.
Severity and active options determine whether risk is justified.
Pregnancy risk changes with developmental timing
Second and third trimester exposure may discolor deciduous teeth and reversibly inhibit bone growth. Animal data also showed reduced fetal weight and delayed ossification. Retired pregnancy letters do not communicate this timing.
Lactation needs a duration and exposure plan
The label advises avoiding breastfeeding for longer than three weeks during treatment. Pumping and discarding during therapy and for nine days after the last dose can reduce infant exposure when chosen.
Routine pediatric use is not recommended
Safety and efficacy of proposed pediatric regimens were not evaluated because of the adult mortality signal. Use below age 18 only when no suitable antibacterial alternative is available.
Suggested pediatric doses are not a broad endorsement
When no alternative exists, suggested IV dosing begins at 1.2 mg/kg every 12 hours for ages 8 to 11, capped at 50 mg, and 50 mg every 12 hours for ages 12 to 17. Specialist oversight remains essential.
Quick check
Lesson
Close the Loop Before the Loading Dose
A complete tigecycline plan aligns a supported syndrome, susceptible organism, source control, alternative analysis, exposure, preparation, monitoring, response, and explicit exit criteria.
- Diagnosis
- Reserve decision
- Exposure
- Monitoring
- Exit criteria
Confirm site, organism, severity, and source.
Show why safer active alternatives are unsuitable.
Make every vial, volume, and infusion reconstructable.
Use cultures, response, fibrinogen, liver, and symptoms.
Start with a supported compartment
Name cSSSI, cIAI, or community-acquired bacterial pneumonia, then document likely organisms, cultures, severity, source, and why tigecycline is active there.
Make reserve use visible
Record why suitable alternatives are unavailable or inappropriate. Do not hide the mortality tradeoff behind the phrase broad spectrum.
Make exposure reconstructable
Write loading and maintenance doses, interval, duration, hepatic adjustment, vial count, concentration, final bag, infusion time, compatibility, and administration record.
Write the exit before toxicity accumulates
Assign response measures, cultures, fibrinogen and coagulation, liver tests, pancreatic and gastrointestinal symptoms, interacting-drug monitoring, and thresholds to narrow, stop, or switch.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 140 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.